Literature DB >> 17998512

The inferior oblique muscle adherence syndrome.

Burton J Kushner1.   

Abstract

OBJECTIVE: To describe the clinical features, etiology, prevention, and treatment of the inferior oblique muscle (IO) adherence syndrome.
METHODS: This series consists of 12 patients treated for a restrictive hypotropia in which the middle portion of the IO was scarred anteriorly, either into or near the inferior rectus muscle (IR) insertion, after prior surgery.
RESULTS: Among the 12 patients treated, the mean hypotropia of the affected eye was 18.1 +/- 7.2 prism diopters and the mean excyclotropia was 13.8 degrees +/- 3.3 degrees . Causes of the IO adherence syndrome included IR surgery (with or without prior IO myectomy) and scleral buckling surgery. The syndrome responded well to surgically releasing or myectomizing the incarcerated IO, combined with ipsilateral IR recession.
CONCLUSIONS: The IO adherence syndrome is a complication of surgery on the IR or of scleral buckling surgery, which can result in a restrictive hypotropia and excyclotropia. It can be prevented by paying attention to the anatomic relationship between the IO and IR and can be effectively treated if it occurs.

Entities:  

Mesh:

Year:  2007        PMID: 17998512     DOI: 10.1001/archopht.125.11.1510

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  3 in total

1.  Retro-equatorial inferior oblique myopexy for treatment of inferior oblique overaction.

Authors:  Manal Kasem; Heba Metwally; Ibrahim T El-Adawy; Ameera G Abdelhameed
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-05-27       Impact factor: 3.117

2.  Strabismus surgery outcomes after scleral buckling procedures for retinal reattachment.

Authors:  Jee Ho Chang; Amy K Hutchinson; Monica Zhang; Scott R Lambert
Journal:  Strabismus       Date:  2013-12

3.  Fat adherence syndrome following inferior oblique surgery: Treatment and outcomes.

Authors:  Pilar Merino; Irene Blanco; Pilar Gómez de Liaño
Journal:  J Optom       Date:  2015-09-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.